Biogen is an American global biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.
Biogen and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ALPROLIX.
Commercialized in the United States as AMPYRA (dalfampridine) Extended Release Tablets, by Acorda Therapeutics.
Acquired in acquisition of Fumapharm AG in 2006.
Currently commercialized in the United States by Genentech, a wholly owned subsidiary of Roche.
Anti-TNF Refractory Rheumatoid Arthritis
Currently commercialized by Roche and its subsidiary, Genentech.